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Abstract
Eleven samples of DNA from choriocarcinomas were studied by high resolution CGH-array 244 K. They were studied after
histopathological confirmation of the diagnosis, of the androgenic etiology and after a microsatellite marker analysis
confirming the absence of contamination of tumor DNA from maternal DNA. Three cell lines, BeWo, JAR, JEG were also
studied by this high resolution pangenomic technique. According to aCGH analysis, the de novo choriocarcinomas exhibited
simple chromosomal rearrangements or normal profiles. The cell lines showed various and complex chromosomal
aberrations. 23 Minimal Critical Regions were defined that allowed us to list the genes that were potentially implicated.
Among them, unusually high numbers of microRNA clusters and imprinted genes were observed.
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Introduction
Choriocarcinoma results from the malignant transformation of
trophoblast cells. They are of interest because allogenic
trophoblasts engage in ‘‘controlled invasion’’ of the placenta as
part of the normal process of implantation. The numerous
syncytiotrophoblastic cells which are deported to the maternal
circulation daily do not ordinarily produce metastasis. Converse-
ly, when a trophoblastic malignancy develops, the uncontrolled
allografted trophoblast continues to invade and grow anarchical-
ly, eventually metastasizing and ultimately leading to death, often
due to lung and/or brain metastases. Choriocarcinomas which
are, therefore, unique in this respect, could result from normal or
complicated pregnancies but half of them arise following a molar
pregnancy.
A molar pregnancy is characterized by hydropic degeneration
of the placenta [1] due to various causes : diploid androgenesis,
with only a paternal chromosomic contribution [2] leading to
androgenic complete moles (anCHM); androgenic triploidy with
two paternal and one maternal chromosome sets leading to partial
moles (PHM) [3]; to a lesser extent with a normal bi-parental
contribution, but associated with a maternal NLRP7 mutation,
leading to all types of moles (bi-PHM and bi-CHM) [4,5]. The
initial imbalanced expression of genes subjected exclusively to
paternal imprinting in anCHM, leads to anarchic dysregulation of
numerous other genes. This results in the single abnormal
development of a trophoblast without an embryo.
Hydatiform moles (HM), mainly anCHM, could become
invasive and malignant once transformed into choriocarcinomas.
An incidence of post-molar choriocarcinoma attaining 5% and
18.6% was reported respectively in Senegal [6,7] and in the Congo
[8]. However, it may be higher if we consider a work in which 15
of the 54 moles (about 28%) collected for their gene expression
studies became neoplastic [9,10]. The prognosis of post-molar
choriocarcinomas is very heterogeneous, from spontaneous
regression, cure or remission under chemotherapy to lethality
generally following lung or brain metastases. For example,
morbidity due to choriocarcinomas is estimated at about 50% in
Senegal [6,7] and in the Congo [8].
It is still very difficult to determine which molar pregnancies are
likely to develop into choriocarcinoma. As these tumors and
particularly post-anCHM lesions can be considered as transplant-
ed cancers, immunological factors such as HLA compatibilities
[11] could play a role.
What are the genetic events that lead to progression from
anCHM, which have a diploid karyotype (90% 46,XX, and 10%
46,XY), to choriocarcinomas? As most human tumors exhibit
abnormal karyotypes, which play a major role in malignant
transformation, progression and invasion, the study of chromo-
somal abnormalities in choriocarcinomas could enable us to
determine minimal critical regions in this tumor. Using array
comparative genomic hybridization (aCGH), a highly resolutive
method, the purpose of the present research was to study possible
acquisitions of chromosomal abnormalities in choriocarcinomas.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29426The recurrent abnormalities will be associated with candidate
genes.
Materials and Methods
The samples were completely anonymous. The study was a
retrospective work, according to a specific protocol approved by
the CHU of Brazzaville (Congo) Ethics Committee. The patients
gave their informed consent in accordance with the regulations in
the Declaration of Helsinki. The data were analyzed anonymously.
The Ethics Committee was perfectly aware of the retrospective
nature of this work, and of the fact that oral informed consent was
obtained for all cases.
Tumor tissue was obtained from 11 post-molar choriocarcino-
mas : M26, M27, M102, M123, M131 M165, M170, M176,
M181, M232, M235 (table 1). All were of uterine origin with the
exception of M27 which was a vaginal metastasis from patient
M26. The primary tumors were snap frozen in the pathology
laboratories. The diagnosis was confirmed by histopathology. All
samples exhibited more than 80% of tumor cells.
Three cell lines established from human choriocarcinoma,
BeWo, JEG-3 (named here JEG) [12] and JAR were included in
the study. Wo had been grafted from a human cerebral metastasis
to the cheek pouch of the hamster, and then serially transplanted
[13]. BeWo was isolated in vitro from Wo 10 years later [14]. JEG-1
to 8 had been isolated from the transplanted choriocarcinoma in
various conditions [12]. JEG-3 is a clone that retained the capacity
to synthesize human chorionic gonadotrophin, HCG [15]. JAR
was obtained from a placenta tumor grafted by Hertz [13,16,17].
Cytogenetic studies were performed on metaphases derived from
these cells and chromosome identification was based on R
banding. Genomic DNA was extracted from frozen tumors or
cell lines using the Qiagen protocol.
Microsatellite marker analysis
Designed to identify cells of androgenetic origin and to exclude
maternal contaminated DNA, the polymorphism of 11 microsat-
ellites (msat) from 3 to 6 chromosomes was determined in most
cases as previously described [18]. The same analysis was
performed for the three cell lines.
Fluorescence in situ hybridization (FISH) studies
A set of commercial probes was used to search for abnormalities
in chromosome regions : Xq10 (DXZ1) & Yq10 (DYZ1), 14q32
(IGH) & 16q23(MAF), 16q22.1 (CFBF), 18q21 (BCL2, SER-
PINB2) from Abbott/Vysis ; 12p13.2 (ETV6) from Kreatech and
12q10 (D12Z1) & 12q15 (MDM2) from Zytovision. They were
used according to the manufacturer’s protocol on histological
sections (M176, and M232) or cytogenetic spreads (BeWo, JAR,
JEG). A hundred cells were analyzed when available.
Immunohistochemistry (IHC)
The IHC-P protocol from the Kit Novolink Polymer
TM
detection System (Novocastra) was used to detect MMP2 (mab
1/100 MAB13407 Chemicon International. Temecula, CA, USA)
localized on 16q12.2, and SERPINB2 (rabbit polyclonal 1/600
HPA015480 SIGMA, F), localized on 18q21.3. In all cases (M102,
M123, M131, M165, M170, M176, M181, M232, M235), epitope
retrieval was performed in 10 mM pH 6 citrate buffer for
45 minutes at 96uC. After the usual steps, slides were incubated
with primary antibody for 1 hour at room temperature for the
antibodies. After PBS standard rinsing, a post primary block
followed by a Novolink polymer were applied for 30 mn each,
followed by two series of PBS61 washing, by DAB revelation and
by hematoxylin counterstaining. Negative controls were per-
formed using no primary antibody.
High resolution aCGH 244,000 K
The choriocarcinomas and the cell lines were analyzed using
244 K microarrays (Agilent Technologies, Santa Clara, CA, USA,
G4411B). In all experiments, DNA from pooled human female
individuals (Promega, Madison, WI) was used as the reference, with
the exception of sample 123 where male DNA was used.
Oligonucleotide aCGH processing was performed as specified in
the manufacturer’s protocol (version 4.0; agilent.com). Data were
extracted from scanned images using feature extraction software
(version A.9.5.3.1, Agilent). Raw data text files from the latter were
then imported for analysis into CGH Analytics 3.4.40. Aberrations
were detected with the ADM2 algorithm and filtering options of a
minimum of 5 probes and abs (log2Ratio) 0.3. Aberration segments
were individually reviewed using build 36, hg18 of UCSC [19].
Table 1. Generalities.
Sample Type
(a) Etiology
(b) Chromosomal aberrations
26 CK, p U ND
27 CK, m U ND
102,123 CK, p AD or B ND
131, 165, 170, CK, p A ND
176, 181, 235,
232
BeWo CK, cl B 71–72,XXY,add(X)(p21–22),+1,add(1)(p36),+2,24,+5,26,add(7)(p22),211,21362,
i(13q),218, der(19)t(9;19)(q13;p13),+mar[cps16]
JEG CK, cl B 71–74,XXY,add(X)(p21–22),+2,t(4;11)(p15;q13),+5,add(7)(p22),add(7)(q32),+9,t(10;15)(p10;q10),
t(10;15)(p10;q10),211,213,i(13q),218,del(18)(q22q),+mar[cps21]
JAR CK, cl B 66–68,XXY,add(X)(p22),del(1)(p31),t(1;13)(p13;q14),t(3;3)(q12;qter),add(4)(q22),+5,
28,del(8)(q22),210,add(11)(q10),der(13)(q11q34),add(17)(p12),219,221,+mar[cps18]
(a)CK, p=primary choriocarcinoma; CK, vm=vaginal metastasis from choriocarcinoma; CK, cl=choriocarcinoma cell line.
(b)A=andromonospermic, AD=, B=, U= unknown.
doi:10.1371/journal.pone.0029426.t001
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repetitive or GC-rich DNA sequences including telomeric and
centromeric regions were excluded. Copy number abnormalities
(CNAs) and copy number variations (CNVs) represented by regions
of gains and losses were defined as a linear ratio of #0.82 or $1.18
respectively with at least 5 oligonucleotides.
Minimal critical regions (MCRs) were defined when similar
abnormalities were at least present in two samples. Genes of interest
within these MCRs were selected according to at least one of the
following criteria: expression in placenta, implication in apoptosis, in
cancer, in embryogenesis and parental imprinting. The data are
described in accordance with MIAME guidelines and have been
depositedinArrayExpressunderaccessionnumberE-nTABM-1117.
Results
Microsatellite profiling
Seven choriocarcinomas out of 9 informative cases (table 1) had a
monospermic androgenic origin by microsatellite genotyping
(figure 1). The origin of the choriocarcinomas M102 and M123
with heterozygous microsatellite markers was either androgenic,
dispermic or bi-parental. The three cell lines had heterozygous
markers that were interpreted as a biparental origin. It was
compatible with their origin from normal gestations. BeWo and
JEG had the same alleles confirming the relationship of the two cell
lines,whileJAR haddifferentallelesshowinganindependentorigin.
Cytogenetics
BeWo, JEG and JAR all had a paratriploid karyotype with
consistent deletion of the distal part of the X chromosome.
Although these cell lines were subjected to multiple passages in
culture, the results are compatible with previous reports. The full
karyotypes are reported in table 1. JEG had a karyotype
marginally resembling that of BeWo (http://www.dsmz.de/
human_and_animal_cell_lines/main.php?menu_id=2).
Array-CGH
CNVs. As no matched pairs of normal DNA had been
obtained, CNVs [20] were distinguished from CNAs based on
Figure 1. Genotype profile obtained with an automated sequencing apparatus of choriocarcinoma M176 with msat 9A from the
PMP22 locus on 17p [18]. A Patient/mother genotype with a 154 bp and a 180 bp 9 A alleles ; B father genotype with a 159 bp and a 169 bp 9 A
alleles; C Tumor M176 : only a single 159 bp paternal allele is detected. Its absence in the mother allowed us to conclude that it is an
andromonospermic tumor; sz=size in base pairs; ar=area; ht=height.
doi:10.1371/journal.pone.0029426.g001
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consultation of the Database of Genomic Variants (www.projects.
tcag.ca/variation/) [22]; iii) the type of embedded genes such as
olfactory receptor genes, the NF1P1 locus or GSTT1 on
chromosome 22 and iv) the presence of repetitive identical
breakpoints between patients. Mendelian CNVs, that could
harbor coding genes, including microRNA (miRNA), were
scattered throughout the entire genome [20,23] in the
choriocarcinoma samples and cell lines. Some of them, for
example, UGT2B17 or ADAM5P exhibited high copy number
polymorphism within the human lineage (table S1) [23]. As a
relationship has been suggested between some CNVs and
malignancy [24], several of them are listed in table S1. For
example a GSTT gene cluster was reported to be a susceptibility
co-factor in cancer [24,25,26]. It is noteworthy that a miRNA, i.e.
mir-1268, possibly exerting a multigene regulatory effect [27], was
found embedded in 15q11.2 CNVs.
CNAs. Among the 10 primary choriocarcinomas, M26,
M123, M176, and M232 exhibited 20 CNAs, with one case
exhibiting 11 CNAs (table S2, figure 2). The chromosomes
involved were 1, 11, 14, 17, 18, 19, 20 and X. Loss of the X
chromosome was detected in case 232 which showed, by FISH, a
single X chromosome without Y in all analyzed cells. In M176
cells, the gain of chromosome 14 was confirmed by FISH with an
IGH probe that showed three copies of 14q32 in 42% of cells,
while two chromosomes 16 (MAF probe) were observed. A small
clone (5%) was detected with four to five chromosomes 14 and
three chromosomes 16 (table 2, figure 3). The loss of 18q exhibited
by the primary choriocarcinoma M26, was not observed in M27, a
metastasis from M26 (table S1). Six primary choriocarcinomas,
M102, M131, M165, M170, M181, M235 had no detectable
acquired CNA according to aCGH 244 K.
The cell lines had multiple unbalanced chromosomal abnor-
malities with 47 CNAs in JAR, 26 CNAs in BeWo and 31 CNAs in
JEG (table S2, figure 4); the all had Y chromosomes, as detected
on the aCGH profiles and confirmed by FISH (table 2). The fact
that the control DNA was female did not allow us to estimate the
number of Y chromosomes by aCGH. The interpretation of the X
chromosome ratio also had to take this fact into account.
BeWo and JEGshared exactly the same aCGHdeletion on the X
chromosome, a 1.3 Mb gain of 5q35.1q35.2 (table S2), a moderate
gain of 16 that was confirmed by FISH with a CBFB probe
(16q22.1) with 4 copies in most cells (table 2). However, JEG had
additional chromosomal abnormalities compared to BeWo, such as
an amplification at 1q32.1 (table S2). The peak was 1.36 Mb long
with a 4.62 ratio. Another major rearrangement of JEG was the lost
distal half of the long arm of chromosome 18 (with only a single
complete chromosome left). Loss of BCL2 (18q21.3) was found by
FISHinJEGconfirmingtheaCGHdata.Threespotswerefoundin
BeWo (Table 2), in accordance with aCGH that showed a loss of
18q beginning at 0.7 Mb telomeric to BCL2.
JAR had a complex pattern of chromosomal amplification from
12pter to 12q21.3. Among the numerous genes contained in these
amplicons, probes from ETV6 on 12p and MDM2 on 12q were
strongly amplified as HSRs that contributed to a marker
chromosome (Table 2, figure 3).
MCRs. MCRs were built from overlapping of at least two
CNAs from different CK or cell lines. The genes had been selected
according to the stringent rules described previously and are
reported in table 3.
Immunohistochemistry (IHC)
Metalloprotein gene (MMP2) expression was tested using IHC
in choriocarcinomas and in normal placenta. The cytotropho-
blastic (CTB) placental cells were weakly positive, while the
choriocarcinoma CTB were heavily labeled (figure 5) in the nine
cases examined.
Serpin B2, localized in 18q12, near BCL2, was prominently
expressed in syncytiotrophoblasts from normal placenta, although
it was not expressed in most choriocarcinomas or very weakly
positive in cases 131, 165 and 170 (figure 5).
Discussion
Six primary choriocarcinomas had no detectable acquired CNA
according to aCGH 244 K although they contained more than
80% of tumor cells. Previously observed on metaphasic CGH [28],
the situation is reminiscent of Acute Myeloblastic Leukemia where
half of the patients have either a balanced translocation and
equivalents, or normal karyotypes with some known punctual
mutation(s), all of which are undetectable by aCGH [29]. The
exclusively paternal genome contribution in choriocarcinomas
could enable androgenic homozygozity, that is functionally
equivalent to LOH, which would not be detectable by aCGH.
CNAs
The loss of the X chromosome (M102) and the gain of 14q
(M176) were confirmed by FISH (figure 3).
A small gain of 11q13.1 (table S2) was shared by the primary
choriocarcinoma M26 and M27, a metastasis from M26. The loss
of 18q, exhibited by the primary choriocarcinoma M26, was not
observed in M27 suggesting that it was an additional abnormality
to the gain of 11q13.1 that occurred after migration of the
metastatic clone. Such situations are not infrequent in tumor
cytogenetics.
These observations contrasted with the numerous CNAs in cell
lines (table S2, figure 4). This is reminiscent of other models such
as Burkitt lymphoma where a similar discrepancy exists, although
it is less pronounced [21].
The fact that JEG, derived from BeWo [12], shared the same
Xp loss at the oligo level, suggests that it was an early
chromosomal abnormality. The same observation can be made
for the gain of chromosome 16 and the gain of 5q. JEG had
additional chromosomal abnormalities compared to BeWo, such
as an amplification at 1q32.1 (table S2 and S3). Among numerous
genes sitting in this amplicon, ELF3, an ETS family member that
has been implicated in cancers and myeloid leukemia cell lines is
highly expressed in the placenta [19]; MDM4, an inhibitor of the
TP53 gene, has been reported to be amplified in brain tumors
[30]. The loss of the distal half of the long arm of chromosome 18
in JEG is quite different of the 18q abnormalities of BEWO. It had
its own chromosome abnormalities such as a -7q21.1 not found in
JEG, showing an independent chromosomal evolution. This
example shows that high resolution array CGH of cell lines could
establish a pangenotype and allows one to verify the identity of a
cell line or the relationship between cell lines and different
subclones, and to follow their evolution through passages.
A progressive deep loss of 8q21.1q22.1, suggesting a highly non
random rearrangement, was observed exclusively in JAR (table S3,
figure 4). Among multiple genes in this 12.76 Mb region, MMP16
is a placenta-specific metalloproteinase involved in reproduction,
embryonic development, and tissue remodeling; TP53INP and
WDR21C are apoptosis inhibitors and RUNXT1 is involved in
t(8;21) leukemia translocations [31]. JAR also lost 10q25.2q25.3
(table S3), a region that contains TCLF7L2, a HMG gene that is
highly expressed in the placenta and is implicated in multiple
cancers.
CGH Array of Choriocarcinomas
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By compiling CNAs in each abnormal sample, we defined 23
MCRs (table 3).
Chromosome 5 was partially gained in the 3 cell lines. Two
MCRs contained part of 5p (table 3), that contained the
telomerase gene, TERT. A large MCR on 5q (table 3) contained,
the proto-oncogene CSF1R (colony stimulating factor 1 receptor
precursor) [26,32] and the growth factor PDGFRB (platelet-
derived growth factor receptor), both of which belong to the
CSF1/PDGF receptor family of tyrosine-specific protein kinases.
CSF1R codes for a cytokine that controls the monocyte-
macrophage system and PDGFRB is involved in various myeloid
malignancies. These two cytokines are highly expressed in the
placenta, control human trophoblast invasion [33] and the EGFR-
Figure 2. aCGH choriocarcinomas M26, M176, M232. Respectively, loss of 18q, gain of 14q and loss of X. The vertical lines along the
chromosomes indicate losses on the left, gains on the right side of chromosomes.
doi:10.1371/journal.pone.0029426.g002
CGH Array of Choriocarcinomas
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trophoblastic disease [34]. Also localized in this MCR, STK10
and DUSP1, that shared similarity with a protein 1 kinase domain,
had a strong expression in the placenta; CNAs of these genes have
been reported to occur in cancer [35,36]. The distal 5q35.2q35.3
contains the homeobox MSX2, MGAT1 and BTNL3 respectively
involved in embryonic development and cancer. All are expressed
in the placenta and belong to the HCG family [19].
The -7q32.3q34 MCR (table 3) contained the CREB3L2 gene,
a transcription regulator involved in prostate cancer. This region
and the BeWo 7q21.1 loss (table S2) did not included the
retrotransposon-derived PEG10 gene (paternally expressed im-
printed gene 10) whose loss causes early embryonic lethality due to
placental defects [37,38].
Loss of the 8p23.3p12 region, previously reported in primary
choriocarcinoma [39,40], harbored (i) the CTSB gene, a cathepsin
implicated in invasion and metastasis and (ii) DLC1 and TUSC3,
two tumor suppressor genes that are expressed in the placenta, and
often deleted in many cancers.
In JEG and JAR, a large MCR+9q32.2q34.3 contained a very
highly expressed metalloproteinase PAPP-A (pregnancy-associated
plasma protein-A) which plays a role in cell proliferation, invasion
and metastasis [24,41].
Among the numerous genes present in the 20.7 Mb loss on 11p,
common to BeWo and JAR, were LGR4 which plays an
important role in female reproduction and in early-stage
embryonic development [42] and WT1, the well-known suppres-
sor gene which is implicated in nephroblastoma (Wilms tumor) but
also in mesenchymal stem cells tumor [43].
The 11q13.1 gain, exclusively contributed by de novo choriocar-
cinomas, contained RELA, a nuclear transcription factor NF-
kappa-B complex subunit. MAP3K11 kinase preferentially
activates MAPK8/JNK kinase, and functions as a positive
regulator of the JNK signaling pathway; it is found to be involved
in the transcription activity of NF-kappaB [19]. This MCR
contains 4 miRNA genes (table 3).
BeWo had a gain of an entire 12p arm while JAR had a ‘‘wave-
crest’’ amplification appearance spanning 12pter to 12q21.3 that
resulted in 10 different regions, exclusively taking into account the
summit of the gains. This pattern suggests an extensive breakage-
fusion-bridge process [44] together with possible inversions from
the chromosome 12 region or even chromothripsis [45]. A large
number of genes were implicated in these very complex
rearrangements (table 3, figures 3 and 4).
A recurrent gain of 14q was observed in two tumors. M176 had
gained a whole chromosome 14, and M123 had partial gains
which had also occurred in the BeWo and JEG cell lines. The most
centromeric 10.21 Mb MCR contained among numerous genes,
EFS (embryonal Fyn-associated substrate isoform 2), that is
important in intracellular signal transduction and MMP14 that
codes for a matrix metalloproteinase 14 preproprotein. Both genes
are highly expressed in placenta. Three miRNA are localized in
this region (table 3).
The next 1.33 Mb gained MCR harbored NFKBIA which
codes for an inhibitor of the NFKB complex. The +14q21.3q24.3
MCR, harbored FOS (PDGF), a proto-oncogene and PGF
(placental growth factor/vascular endothelial growth) that belongs
to the PDGF-VEGF family; it is a growth factor with a cell
Table 2. FISH studies in cell lines.
Localization Probes and number of signals Conclusion* JAR** BEWO** JEG**
Xq10 (DXZ1), Yq10 (DYZ1) DXZ1x2,DYZ1x0 XX 20
DXZ1x2,DYZ1x1 XXY 65 30 80
DXZ1x2,DYZ1x2 XXYY 60
DXZ1x4,DYZ1x2 XXXXYY 20
others 15 10
16q22.1 (CFBF) CBFBx3 16q22x3 10
CBFBx4 16q22x4 60 72 85
CBFBx5–6 16q22x5–6 16
CBFBx8–10 16q22x8–10 20 12 15
CBFBx10–14 16q22x10–14 10
18q21 (BCL2, SERPINB2) BCL2x1 18q21x1 ND 88
BCL2x2 18q21x2 12
BCL2x3 18q21x3 75
BCL2x4 18q21x4 5
BCL2x5–6 18q21x5–6 15
BCL2x10–14 18q21x10–14 5
12p13.2 (ETV6) ETV6x3 12px3 10 ND ND
ETV6x11–14 12p amp 65
ETV6x22–26 12p amp 25
12q10 (D12Z1), 12q15 (MDM2) D12Z1x3–4, MDM2.20 12q15 amp 46 ND ND
D12Z1x5–6, MDM2.20 12q15 amp 34
D12Z1x8–12, MDM2.20 12q15 amp 20
*The number of X or Y is based from the centromere number.
**Numbers of cells out 100 cells counted.
doi:10.1371/journal.pone.0029426.t002
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expressed.
The gain of 14q32.2q32.3, a region subject to parental
imprinting, was observed in two tumors and two cell lines. It
contained the postfertilization-derived secondary MEG3-DLK1
intergenic differentially methylated region [46]. Three such genes,
strongly transcribed in the placenta, are next to MEG3 : DLK1
(Delta-like homologue 1, also known as preadipocyte factor 1),
DIO3 (type III iodothyronine deiodinase 3), both containing an
EGF-like domain, and RTL1 (retrotransposon-like 1). Their
overexpression causes several embryonic defects, retarded growth
and lethality [27,47]. RTL1 is a key gene in placenta formation
[48]. It is a retrotransposon-derived, paternally-expressed imprint-
ed gene that has an overlapping maternally expressed antisense
transcript. This transcript contains several miRNAs targeting the
transcripts of this gene through an RNA interference (RNAi)
mechanism. RTL1 is essential for fetal capillaries. Its overproduc-
tion is associated with abnormal fetal development in mice.
Furthermore, in humans and in mice [49], the DLK1-DIO3-
RTL1 imprinted domain contains more than 50 miRNAs that
exert multiple interactions with numerous genes including
oncogenesis [50,51]. These results suggest that the biallelic
paternal imprinted genes and the multiple miRNAs located in
14q32 in humans and in 12qF1 in mice, could contribute to the
pathogenesis of trophoblastic disease [52] and to CK.
The 16q was gained in the three cell lines (table 3). It harbored
MMP2, a metalloprotein gene, found to be overexpressed by RT-
PCR in the three cell lines and by Western blot in JAR and BeWo
[53]. By IHC, choriocarcinoma cytotrophoblastic cells were
heavily labeled (figure 5) in the nine de novo cases examined,
contrasting with the control placental cells that were weakly
positive. However, no gain of 16q was detected in primary tumors
neither by aCGH nor by FISH (M176). This apparent discordance
between IHC expression and DNA copy number is not unusual
and among many reasons, can be caused by small duplications
that are undetectable by aCGH even at high resolution. An
example is the duplication of MLL that is sometimes enhanced by
a trisomy 11 in AML [31].
A deep deletion, 218q12.2q21.3, with a 0.37 linear ratio,
formed a 26.96 Mb MCR (table 3) that was confirmed by FISH
Figure 3. FISH on choriocarcinomas. A=M176 Xq10 r & Yq10 g : left nucleus with 3Xq10, right ones with 5 spots. B=M232 Xq10 r & Yq10 g :
only one Xq10 spot for each cell. C=M176 14q32 g & 16q23 r : 2 to 3 green spots (14q) and 1 to 2 red ones(16q). D=JAR 16q22 CBFB r+g:3t o4
spots for 16q. E=JEG 16q22 CBFB r+g : 4 spots for 16q. F=BEWO 16q22 CBFB r+g: 4 spots for 16q and a cell with eigth spots; these two types of cells
are not distinct by aCGH. G=JEG BCL2 r+g : only one spot of 18q. H=BeWo BCL2 r+g : three spots of BCL2 per cell, that are considered as a small loss
compared to JEG. I=BeWo Xq10 r & Yq10 g : two Xq10 and one Yq10 spots. J & K=JAR 12p12 ETV6 r+g : ETV6 is amplified68 in the right nucleus of
picture J and, on picture K, this amplification is located on a marker chromosome while 3 copies are sitting on probably normal 12p. L=JAR 12q10 r &
12q15 MDM2 g. An amplification of MDM2 is observed (green) from 6 copy on a der(12) with one (or 2) chromosome 12 centromere(s); 3 copies of
MDM2 seem present on apparently normal chromosomes 12.
doi:10.1371/journal.pone.0029426.g003
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MCR contains also PMAIP1/Noxa, a tumor suppressor gene that
contributes to p53-dependent apoptosis after genotoxic exposure
[54] and is implicated in various cancers. In BeWo, the CNA
breakpoint was between BCL2 and SERPINB2 (Placental
plasminogen activator inhibitor). SERPINB2 plays a role in the
placenta during early pregnancy at 8–10 weeks [55], is very highly
expressed in this tissue [19], is purported to be involved in
gestational trophoblastic disease [56] and in malignant neoplastic
progression [57]. However it was not found or very poorly
expressed in the de novo choriocarcinoma studied in the present
work (figure 5). The genetic or regulatory origin of this lack of
expression remains to be determined.
A 3.64 Mb gain was observed on 19p13.1, with more than a
hundred genes encoded in this strong chromosomal R band.
Although very small CNVs were present in this small area, no
Figure 4. aCGH choriocarcinoma cell lines BeWo, JEG, JAR. Recurrent gain of 5q, 12p, 14q, 20q and loss of 8, 18q, Xp. The CNAs following
optimal normalization for the X (see results) are indicated in blue along the X chromosomes in the three cell lines.
doi:10.1371/journal.pone.0029426.g004
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Cytogenetic Samples Gain Width Localization Nb of Selected genes(3) miRNA
limits(1) (2) Loss (Mb) (Mb) genes
+1p36.2p36.1 123 176 G 10.34 8.72–19.06 .100 PDPN PAX7 mir-34a
+1p35.3p34.3 176 A G 9.43 35.41–44.84 .100 STK40 CSF3R MYCL1 mir-30e, 30c1
+1q21.2 123 A C G 0.8 148.34–149.23 .20 CTSK MCL1 mir-554
+1q21.3 123 B A G 0,34 151,68–152,02 16 S100A1 S100A2 S100A3 S100A4
C
+1q32.1 A C(4) G 4.56 198.64–203.20 .15 ELF3 PTPN7 MDM4 SOX13 KISS1 FMOD mir-1231
+1q42.11q44 123 A G 11.29 223.65–234.94 .33 NLRP3 NID1 mir-1182, 1537
+5p15.3p14.2 A B C G 14.78 0.09–14.79 .29 TERT
+5p13.3p12 A B C G 31.16 12.87–44.03 .90 PDZD2 mir-887, 579, 580, 1274a
+5q23.2q35.2 A B C G 52.79 121.69–174.48 .100 TGFBI PPP2CA WNT8A CD14 GM2A CSF1R mir-1289-2, 886, 874, 584
PDGFRB ABLIM3 STK10 DUSP1 FGF18 NKX2-5 mir-143, 145, 378, 1294, 1303
HMP19 HLC4 CLTB RAB24 DDX41 MSX2 mir-146a, 103-1, 103-1-as, 218-2
mir-585, 218-2, 585
+5q35.2q35.3 A C(4) G 6.12 174.50–180.62 .75 MGAT1 BTNL3 hCG_18385 mir-1271, 1229, 340
27q32.3q34 B C L 6.78 132.04–138.80 .20 CREB3L2 mir-490
28p23.3p12 A B C L 35.68 7.25–36.32 .100 CTSB DLC1 TUSC3 LPL DUSP4 NRG1 mir-320a, 548i-3, 597, 124-1
TNFRSF10B RBPMS DUSP26 mir-1322, 598, 383, 320a, 548h-4
28q13.1q22.1 A B C L 20.20 66.29–96.49 .100 MMP16 E2F5 TP53INP WDR21C
RBM35A RUNXT1
+9q32q33.1 B C G 30.07 85.20–115.25 .50 PAPPA TNFSF8 mir-199b, 219-b mi
+9q32q34.3 A B C G 24.04 115.26-139.30 .100 RAPGEF1 ENG CDK9 TRAFF2 PAEP
210q22.3q23.2 A B C L 8.71 79.96–88.67 .35 ZMIZ1 mir-126
211p14.3p12 A B L 20.69 21.72–42.41 .30 CCDC34 LGR4 WT1(p) GAS2 ELF4 mir-346
+11q13.1 26 27 123 G 2.08 63.47–65.54 100 RELA MAP3K11 PRDX5 VEGFB CST6 mir-1237, 192, 194-2, 612
+12p13.2p13.1 A B(5) G 1.55 11.72–13.28 .15 CDKN1B CREBL2 EMP1 ETV6 LRP6 DDX47 mir-1244, 613, 614
BCL2L14 DUSP16
+12p12.3 A B(5) G 1.27 15.00–16.27 7 ARHGDIB RERG
+12p12.3p12.2 A B(5) G (A) 1.61 18.89–20.50 3 PDE3A AEBP2
+12p12.2p12.1 A B(5) G 10.79 20.83–31.62 .50 KCNJ8 LDHB RECQL DDX11 FAM60A OVOS2 mir-920
+12q13.1 A B(5) G 0.34 52.33–52.67 8 ATP5G2 HOXC10 HOXC11 HOXC12 HOXC13 mir-196a-2
+14q11.2q13.1 176 A C G 13.7 19.99–33.69 .100 BCL2L2 MMP14 EFS mir-208a, 208b, 624
+14q13.1q13.2 123 176 A C G 1.33 33.70–35.04 14 NFKBIA
+14q24.2q24.3 123 176 A C G 5.04 72.40–77.45 78 PGF FOS mir-1260
+14q32.13 176 A C G 22.79 77.46–100.25 .50 SERPINA3 GSC mir-342, 345
+14q32.2q32.3 123 176 A C G 5.41 100.26–105.67 .30 DIO3(p) DLK1(p) RTL(p) MEG3(m) 53 mir Rna
ATK1 MTA1 JAG2
+16q11.2q24.3 A B C G 43.64 50.14–88.65 .100 AMFR CDH5 MMP2 SLC7A5 MMP15 CSNK2A2 mir-138-2, 328, 1538, 1910, 1972
+17p11.2 123 A C G 1.33 19.12–20.46 .10 MAPK7 mir-1180
218q12.2q21.3 26 C L 25.5 34.20–59.70 .30 BCL2 PMAIP1 MBD2 MEDEA TCEB3C(m) RIT2 mir-924, 1539, 122
218q21.3q23 26 A C L 25.96 59.70–69.79 .15 SERPINB2 SOCS6 CDH7 CDH19
+19p13.1 26 123 A G 3.64 16.00–19.64 100 GDF1 UPF1 INSL3 mir-640
+19q13.4 123 A B(6) G 0.22 58.76–58.98 2 DPRX ZNF331(m) mir-512-1, 512-2, 1323, 498, 520e
C miRna clusters mir-515-1, 519e, 520f, 515-2, 519c
mir-1283-1, 520a, 526b, 519b,
525
mir-523, 518f, 519a-1, 527, 935
mir-520b, 518b, 526a-1
mir-520c, 518c, 524, 517a, 519d
mir-521-2, 520d, 517b
mir-520g, 516b-2, 526a-2
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genes were selected based on their high placental transcription
ratio (table 3) [19]. On 19q13.4, a smaller gained MCR (table 3),
contained DPRX, an homeobox DNA binding protein with
multiple related processed pseudogenes which might be involved
in embryonic cells. Two miRNA clusters, one containing more
than 50 miRNAs named C19MC [52] and a smaller one miRNAs
371–373 were located within these 0,22Mb. C19MC was found to
be paternally imprinted and expressed in placenta, CHM and the
JEG cell line [52]. It was found to be overexpressed in multiple
tumors including malignant germ cell tumors [58]. Next to this
region was a 1.35 Mb gained MCR (table 3) containing the
NLRP7 gene involved in endometrial cancer [59] and associated
with biparental complete hydatidiform moles [60,61].
On chromosome 20q11.2, a 5.1 Mb gained MCR contained
more than 100 genes. Paternally imprinted DNMT3B encodes a
DNA methyltransferase which is thought to function in de novo
CpG methylation. Its homolog DNMT3A was recently found to
be mutated in a subset of leukemia with a normal karyotype [62].
The PROCR (alias EPCR) encodes an endothelial protein C
receptor that is a serine protease expressed in placental arteries
and veins [63] and is detected in giant trophoblast cells at the feto-
maternal boundary in mice. The metalloproteinase MMP24 gene
plays a role in fetal losses and embryonic development.
The X chromosome was the most involved in four samples
(tabme 3). A complete loss was observed in the primary tumor 232,
while a partial loss of Xp was found in the three cell lines which all
had two X chromosomes, as depicted by FISH (table 2). JAR also
had a 0.12 Mb Xp22.3 deletion of the other X chromosome
superimposed on the larger deletion from the other X. It defined
the smallest MCR in this region which contained only the 39 part
of the STS (steroid sulfatase) gene. Some CNVs were in the
centromeric part of this MCR but almost none of them had
extended to the STS coding region. This gene, which is necessary
for the production of free steroids from sulfoconjugated precursors,
is highly expressed in normal placenta, contributes during
pregnancy to the synthesis of estrogen, and is involved in
embryonic and fetal development. STS plays an important role
in the development and progression of various cancers such as
breast carcinoma [25] or estrogen-dependent cancers such as
human endometrial carcinoma [64]. Although it is most probably
a somatic alteration, it cannot be ruled out that this 120 Kb
deletion could also be a constitutional CNA, corresponding to X-
linked ichthyosis.
A 30 Mb deletion -Xp22.3p21.3 (table 3), was present on the
other X chromosome of JAR defining the Xp MCR that
contained more than 25 genes, including STS. The PRDX4
(Peroxiredoxin-4) gene is a transcription factor involved in oocyte
maturation and in early embryo development [65] and protects it
against oxidative stress [66,67]. CNKSR2 (connector enhancer of
kinase suppressor of RAS) seems to be an antiapoptotic gene and a
possible regulator of various pathways including that of RAS [68].
In previous studies using mainly metaphasic comparative
genomic hybridization, a gain of 7q [39,40,69] has been described
in choriocarcinoma although it was not observed in this work. The
8p12–p21 loss observed in the present study, has previously been
reported in gestational choriocarcinoma [40] and in non
gestational choriocarcinoma [70] where it was associated with
gains of 5p, 20q and losses of 18q and Xp. These rearrangements
were identified as MCRs in the present work (table 3) with deep
losses of 18q, Xp and gains of 5p and 20q. They were not observed
in a choriocarcinoma derived from a Non Seminomatous type II
Germ Cell Tumor originating in a case of 46,XY gonadal
dysgenesis [71]. The presence of a Y chromosome in BeWo JAR
JEG cell lines, the derivations of a choriocarcinoma cell line from
two XY patients compare to one from a female [17], may reflect a
Cytogenetic Samples Gain Width Localization Nb of Selected genes(3) miRNA
limits(1) (2) Loss (Mb) (Mb) genes
mir-518e, 518a-1, 518d, 516b-1
mir-518a-2, 517c, 520h, 521-1,
522
mir-516a-1, 1283-2, 516a-2, 519a-
2
mir-371, 372, 373
+19q13.4 123 A C G 1.35 58.99–60.34 3 NLRP7 NLRP2 PRKCG hCG_2008157
+20q11.2 123 A B C G 5.01 29.29–34.30 .80 DNMT3B(p) PROCR MMP24 BCL2L1 TP53INP2 mir-1825, 644, 499, 1289
+20q13.2 123 A B C G 2.39 49.7–52.09 7 TSHZ2
2Xp22.3 232 A B C L 3.05 24.8419–7.24 .15
2Xp22.31 232 A B C L 0.12 7.25–7.37 1 STS
2Xp22.2p21.3 232 A B C L 22.2 7.38–29.86 .15 50 PRDX4 CNKSR2 mir-651, 1308
(1)The localization of MCRs with a contribution of de novo choriocarcinomas are indicated in bold.
(2)BeWo=A, JAR=B, JEG=C.
(3)The genes that meet the selection criteria and were selected are indicated in bold characters. The genes subject to parental imprinting are underlined : (m)=maternal
imprinted gene; (p)=paternal imprinted gene. The genes that does not meet the selection criteria but are of interest for various reasons are indicatedi np l a i n
characters.
(4)BeWo and JEG are included for simplicity although they don’t define a real MCR.
(5)indicate the ‘‘wave-crest’’ amplification of the JAR cell line probably the site of chromothripsis phenomenon [45]. A basal gain under it was observed between 12pter
and 12q21.3.
(6)JAR contribute for only mir 371 372 & 373.
doi:10.1371/journal.pone.0029426.t003
Table 3. Cont.
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predisposition to malignant transformation in gonadal dysgenesis
induced by the Y chromosome [71].
Recurrent MCRs in choriocarcinomas harbor a high number of
microRNA clusters and imprinted or paternally expressed
miRNAs genes [52] which constitute the uniqueness of these
tumors amid most adult cancers. As these chromosomal
abnormalities are present in cell lines, this opens the way for
future functional studies in these complex malignancies.
Supporting Information
Table S1 Copy number variations (CNV). (1) included in
high copy number variations.
(RTF)
Table S2 Copy number aberrations (CNAs) in chorio-
carcinoma by aCGH. (1) M102 was a biparental choriocarci-
noma because a Y was detected. As the reference DNA was
female, an apparent loss of the X appeared; the background was
too high which prohibited detailed analysis. (2) Metastasis from
M26. (3) Probably the site of a chromothripsis phenomenon.
(RTF)
Table S3 Single CNA with genes of interest. (1) Strong
gains or even amplifications.
(RTF)
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